1. How many patients were treated within your Trust with the following drugs within the specified time periods?
Number of patients treated between 01 February 2017 and 31 July 2018
Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast
Adalimumab
Dupilumab
Etanercept
Infliximab
Secukinumab
Ustekinumab
2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?
Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018
Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?
Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018
Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast
Adalimumab
Dupilumab
Etanercept
Infliximab
Secukinumab
Ustekinumab
4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:
OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast
Adalimumab
Dupilumab
Etanercept
Infliximab
Secukinumab
Ustekinumab
5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:
Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018
Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020
6. How many of your Trust’s homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?
Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018
